10-Q: Evolus Reports Q1 2026 Financials, Revenue Up 6.7%

Evolus, Inc. announced its first-quarter 2026 financial results, reporting a 6.7% increase in net revenues to $73.1 million, driven by the launch of Evolysse and international growth of Jeuveau.

Summary

• Evolus, Inc. reported net revenues of $73.1 million for the three months ended March 31, 2026, a 6.7% increase compared to $68.5 million in the same period of 2025.
• The revenue growth was primarily driven by the launch of Evolysse Form and Evolysse Smooth in the United States in April 2025 and continued international growth of Jeuveau.
• The company reported a net loss of $10.7 million for the quarter, an improvement from a net loss of $18.9 million in the first quarter of 2025.
• Selling, general, and administrative expenses decreased by 8.2% to $52.0 million, attributed to strategic cost optimization initiatives.
• As of March 31, 2026, the company had $49.8 million in cash and cash equivalents.
• Evolus anticipates two additional Evolysse products to be approved in the US in 2026 and 2027, and expects to launch all four Evolysse products in Europe in Q2 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with revenue growth and improved net loss, but tempered by continued operating losses and significant debt.

Positives

• Net revenues increased by 6.7% to $73.1 million in Q1 2026 compared to Q1 2025.
• Net loss improved to $10.7 million in Q1 2026 from $18.9 million in Q1 2025.
• Selling, general, and administrative expenses decreased by 8.2% due to cost optimization.
• The company has $49.8 million in cash and cash equivalents as of March 31, 2026.
• The company has access to a $30 million revolving credit facility and an additional $10 million accordion feature, as well as $100 million in liquidity under the New Pharmakon Term Loans.

Negatives

• The company continues to incur net operating losses and has an accumulated deficit of $671.7 million as of March 31, 2026.
• The company used $9.95 million in cash from operating activities in Q1 2026.
• Gross profit margin decreased slightly to 66.9% in Q1 2026 from 68.1% in Q1 2025.
• The company faces significant competition in the medical aesthetics market.
• The company relies on third-party suppliers (Daewoong and Symatese) for its key products, creating supply chain risks.

Risks

• The company has incurred significant losses since inception and may continue to do so, potentially affecting its stock price and ability to raise capital.
• Intense competition in the medical aesthetics market from established players like AbbVie and Galderma could impact market share and pricing.
• Failure to achieve broad adoption of Jeuveau and Evolysse by practitioners and consumers could hinder commercial success.
• Demand for products is sensitive to consumer discretionary spending, which is affected by global economic conditions, inflation, and consumer sentiment.
• Trade policy risks, including tariffs on imports from South Korea and France, could materially impact results of operations and financial condition.
• Reliance on Symatese for regulatory approval of Evolysse products in the US poses a risk if approval is delayed or not obtained.
• The company may require additional financing, and failure to secure it on acceptable terms could force operational delays or termination.
• Non-compliance with Medytox settlement agreements could lead to litigation or loss of the ability to market Jeuveau.
• Termination or loss of significant rights under licensing agreements with Daewoong and Symatese would adversely affect the business.
• Intellectual property infringement claims could delay commercialization efforts or interrupt product supply.
• Reliance on digital technology and applications makes the company vulnerable to information system failures or cybersecurity incidents.
• Extensive government regulation in the pharmaceutical and medical device industries could lead to delays, penalties, or significant additional expenses.

Future Outlook

Evolus anticipates continued sales growth driven by the success of Evolysse Form and Smooth in the US, the European launch of the Evolysse collection, and potential regulatory approvals for Evolysse Sculpt and Lips in the US in 2026 and 2027. The company expects R&D expenses to increase as it develops further product candidates and pursues regulatory approvals. Management believes current capital resources, including cash, the New Pharmakon Term Loans, and the Revolving Credit Facility, are sufficient to fund operations for at least the next twelve months.

Management Comments

• The company's strategy of focusing exclusively on the cash-pay aesthetic market provides flexibility to drive customer adoption through various programs.
• Management believes that current capital resources are sufficient to fund operations through at least the next twelve months.
• The company is pursuing potential refunds of previously paid IEEPA tariffs and evaluating actions to mitigate the impact of current and proposed tariffs.

Industry Context

StockSavvy.ai notes that Evolus's Q1 2026 results reflect continued revenue growth in the competitive medical aesthetics market, bolstered by new product launches like Evolysse. However, the company's persistent net losses and reliance on debt financing highlight the capital-intensive nature of this industry and the ongoing challenges in achieving profitability amidst strong competition and evolving regulatory landscapes.

Comparison to Industry Standards

• Evolus's gross profit margin of 66.9% is within the typical range for pharmaceutical and medical device companies, though slightly lower than the previous year.
• The company's net loss per share of ($0.16) indicates ongoing investment in growth and market penetration, a common characteristic of companies in the early to mid-stages of commercialization in the aesthetics sector.
• Competitors like AbbVie, with its established BOTOX product, hold significant market share and possess greater financial resources, setting a high bar for market penetration and competitive pricing strategies.
• The company's strategy of focusing on the cash-pay aesthetic market differentiates it from companies with reimbursed products, offering pricing and marketing flexibility but limiting the scope of indications and potential revenue streams.

Legal Proceedings

• The company is subject to ongoing litigation matters and regulatory encounters arising from the ordinary course of business, but does not believe these would have a material adverse effect on its financial position, results of operations, or cash flows, except as otherwise noted.

Related Party Transactions

• Contingent royalty obligation payable to Evolus Founders, which consists of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau, terminating in the second quarter of 2029.

Stakeholder Impact

• Shareholders: Continued net losses and accumulated deficit may impact stock price. Access to credit facilities and revenue growth are positive indicators.
• Creditors: The company has significant long-term debt ($156.4 million) and a revolving credit facility, with covenants to adhere to.
• Suppliers: The company relies on Daewoong and Symatese for product manufacturing, creating dependency and potential supply chain risks.
• Customers (Aesthetic Practitioners): Continued product offerings and potential new product launches are beneficial. Pricing strategies and loyalty programs are key to maintaining relationships.

Next Steps

• Anticipate two additional Evolysse products to be approved in the United States in 2026 and 2027.
• Expect to launch all four Evolysse products in Europe in the second quarter of 2026.
• Continue to pursue potential refunds of previously paid IEEPA tariffs.
• Evaluate actions to mitigate the impact of current and proposed tariffs.

Key Dates

Recommendation

Evolus shows revenue growth and improved net loss, indicating positive operational momentum. However, the company continues to operate at a loss, has a substantial accumulated deficit, and carries significant debt. While new product launches and market expansion are promising, the competitive landscape and reliance on third-party suppliers present ongoing risks. A 'hold' recommendation reflects a balanced view of the progress made against the persistent financial challenges and market risks.

Keywords

Evolus, Jeuveau, Evolysse, Form, Smooth, Sculpt, Lips, prabotulinumtoxinA-xvfs, hyaluronic acid, dermal filler, medical aesthetics, performance beauty, SEC filing, 10-Q, financial results, revenue, net loss, cash flow, debt, regulatory approval, Daewoong, Symatese, Medytox